From GlobeNewswire: 2025-06-11 16:20:00

Alvotech announced the completion of a private placement with 40 institutional investors, with 60% demand from Sweden, Norway, and the UK, and 30% from the US. 80% of shares and SDRs were sold to new investors. The shares and SDRs have been delivered, with a transfer of 7.5 million treasury shares. The press release warns of restrictions in certain jurisdictions and disclaims responsibility for the content of partner filings. Alvotech focuses on biosimilar medicines, with two already approved. The company has formed commercial partnerships globally, aiming to be a leader in biosimilars. Forward-looking statements in the communication discuss future business prospects and risks.



Read more at GlobeNewswire: Alvotech’s Private Placement Completed with Delivery of